Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Colorectal Cancer Reports
Published in: Current Colorectal Cancer Reports 4/2014

01-12-2014 | Immunotherapy of Malignancy (R Kim, Section Editor)

Dendritic Cell Cancer Vaccines for Treatment of Colon Cancer

Authors: Osama E. Rahma, Zaw W. Myint, Bassam Estfan

Published in: Current Colorectal Cancer Reports | Issue 4/2014

Login to get access

Abstract

Despite advances in treatment modalities, colorectal cancer (CRC) still accounts for about half a million deaths yearly worldwide. The majority of metastatic CRC are unresectable, and of those who undergo resection, few are cured. Advances in chemotherapy and targeted therapy have improved survival, but options remain limited, making the case for incorporating novel modalities in CRC treatment paradigm. Our improved understanding of the tumor immune microenvironment had led to the development of novel immunotherapeutic agents that have been tested in clinical trials such as cancer vaccines. Cancer vaccines are designed to activate the effector immune cells in order to generate an immune response against tumors. Dendritic cell vaccines offer potential benefits for CRC patients but requires further evaluation. We reviewed the role of dendritic cells in the colorectal tumor microenvironment and dendritic cancer vaccine studies in colorectal cancer.
Literature
1.
Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):104–17.PubMedCrossRef
2.
Tebbutt N, Cattell E, Midgley R, Cunningham D, Kerr D. Systemic treatment of colorectal cancer. Eur J Cancer. 2002;38(7):1000–15.PubMedCrossRef
3.
Benson 3rd AB, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408–19.PubMedCrossRef
4.
Edge SB, editor. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
5.•
Toomey PG, Vohra NA, Ghansah T, et al. Immunotherapy for gastrointestinal malignancies. Cancer Control. 2013;20(1):32–42. The authors explain the safety of vaccination-based and adoptive cell therapy strategies and the use of these strategies for induction of antitumor immune responses in GI malignancies with some promising results.PubMed
6.
Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991;9:271–96.PubMedCrossRef
7.
Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5(4):296–306.PubMedCrossRef
8.••
Galon J, Pagès F, Marincola FM, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012;10:205. The authors introduce the concept of immunoscore which is essential prognostically and potentially can serve as a predictive tool. Introduction of this parameter as a biomarker to classify cancers, as part of routine diagnostic and prognostic assessment of tumors, potential to facilitate clinical decision-making including rational stratification of patient treatment.PubMedPubMedCentralCrossRef
9.
Merika E, Saif MW, Katz A, Syrigos K, Morse M. Review. Colon cancer vaccines: an update. In Vivo. 2010;24(5):607–28.PubMed
10.
Dalerba P, Maccalli C, Casati C, Castelli C, Parmiani G. Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol Hematol. 2003;46:33–57.PubMedCrossRef
11.••
Fridman WH, Galon J, Dieu-Nosjean MC, et al. Immune infiltration in human cancer: prognostic significance and disease control. Curr Top Microbiol Immunol. 2011;344:1–24. The authors describe importance of the immune microenvironment to help better understanding of how anticancer agents work in cancer patients.PubMed
12.
Nagorsen D, Keilholz U, Rivoltini L, et al. Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. Cancer Res. 2000;60(17):4850–4.PubMed
13.
Seino K, Kayagaki N, Okamura K, Vagita H. Antitumor effect of locally produced CD95 ligand. Nat Med. 1997;3(2):165–70.PubMedCrossRef
14.
Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med. 1998;4(1):43–9.PubMedCrossRef
15.
Merogi AJ, Marrogi AJ, Ramesh R, Robinson WR, Fermin CD, Freeman SM. Tumor-host interaction: analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas. Hum Pathol. 1997;28(3):321–31.PubMedCrossRef
16.
Rohrer JW, Coggin Jr JH. CD8 T-cell clones inhibit antitumor T-cell function by secreting IL-10. J Immunol. 1995;155(12):5719–27.PubMed
17.
Heriot AG, Marriott JB, Cookson S, Kumar D, Dalgleish AG. Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br J Cancer. 2000;82(5):1009–12.PubMedPubMedCentralCrossRef
18.
Galizia G, Lieto E, De Vita F, Romano C, Orditura M, Castellano P, et al. Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: relationship with radicality and outcome. J Interferon Cytokine Res. 2002;22(4):473–82.PubMedCrossRef
19.
Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673):245–52.PubMedCrossRef
20.
21.•
Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol. 2012;30:1–22. The author describes how dendritic cells were discovered, the dissection of the afferent and efferent limbs of cell-mediated immunity, the development and maturation of dendritic cells, how to distinguish dendritic cell subsets, how dendritic cells provide routes to the control of antigen-specific T cell immunity in its different helper, killer, and regulatory forms, and how to develop dendritic cell-based vaccines.PubMedCrossRef
22.
Inaba K, Witmer-Pack M, Inaba M, Hathcock KS, Sakuta H, Azuma M, et al. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J Exp Med. 1994;180(5):1849–60.PubMedCrossRef
23.
Inaba K, Pack M, Inaba M, Sakuta H, Isdell F, Steinman RM. High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas of lymph nodes. J Exp Med. 1997;186(5):665–72.PubMedPubMedCentralCrossRef
24.
Théry C, Amigorena S. The cell biology of antigen presentation in dendritic cells. Curr Opin Immunol. 2001;13:45–51.PubMedCrossRef
25.
Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. N Engl J Med. 1994;331:679–80.PubMedCrossRef
26.
Yee C et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A. 2002;99(25):16168–73.PubMedPubMedCentralCrossRef
27.
Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594):850–4.PubMedPubMedCentralCrossRef
28.
Rahma OE, Khleif SN. Therapeutic vaccines for gastrointestinal cancers. Gastroenterol Hepatol (N Y). 2011;7(8):517–64.
29.
Schwartzentruber DJ, Lawson DH, Richards JM, et al. Gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364:2119–27.PubMedPubMedCentralCrossRef
30.
Devarapu SK, Sharma SC, Das SN. Triggering of T cell-mediated immune responses by allogenic tumor cell vaccine in patients with oral cancer. Immunopharmacol Immunotoxicol. 2006;28(3):387–95.PubMedCrossRef
31.
Rahma OE, Hamilton JM, Wojtowicz M, et al. The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. J Transl Med. 2014;12:55.PubMedPubMedCentralCrossRef
32.
Senzer N, Barve M, Kuhn J, et al. Phase I trial of “bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell” vaccine (FANG) in advanced cancer. Mol Ther. 2012;20(3):679–86.PubMedPubMedCentralCrossRef
33.
Vik-Mo EO, Nyakas M, Mikkelsen BV, et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother. 2013;62(9):1499–509.PubMedPubMedCentralCrossRef
34.
Le DT, Brockstedt DG, Nir-Paz R, et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res. 2012;18(3):858–68.PubMedPubMedCentralCrossRef
35.
Onishi H, Morisaki T, Baba E, et al. Long-term vaccine therapy with autologous whole tumor cell-pulsed dendritic cells for a patient with recurrent rectal carcinoma. Anticancer Res. 2011;31(11):3995–4005.PubMed
36.
Schadendorf D, Ugurel S, Schuler-Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol. 2006;17(4):563–70.PubMedCrossRef
37.
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22.PubMedCrossRef
38.
Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011;17(11):3520–6.PubMedCrossRef
39.
Pajtasz-Piasecka E, Indrová M. Dendritic cell-based vaccines for the therapy of experimental tumors. Immunotherapy. 2010;2(2):257–68.PubMedCrossRef
40.
41.
Frankenberger B, Schendel DJ. Third generation dendritic cell vaccines for tumor immunotherapy. Eur J Cell Biol. 2012;91(1):53–8.PubMedCrossRef
42.
Achtar MS, Ibrahim R, Herrin VE, Gause B, Steinberg S, Grollman F, Rahma OE, Bernstein S, Berzofsky J, Khleif SN. Pre-immature dendritic cells pulsed with human papilloma virus 16 E7 peptide vaccine in advanced cervical cancer .J Clin Oncol, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 2522
43.
44.
Samara RN, Khleif SN. HPV as a model for the development of prophylactic and therapeutic cancer vaccines. Curr Mol Med. 2009;9(6):766–73.PubMedCrossRef
45.
Mosolits S, Nilsson B, Mellstedt H. Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials. Expert Rev Vaccines. 2005;4(3):329–50.PubMedCrossRef
46.
Mocellin S, Rossi CR, Lise M, Nitti D. Colorectal cancer vaccines. Principles, results, and perspectives. Gastroenterology. 2004;127(6):1821–37.PubMedCrossRef
47.
Zhou Y, Bosch ML, Salgaller ML. Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity. J Immunother. 2002;25(4):289–303.PubMedCrossRef
48.
Slingluff Jr CL, Colella TA, Thompson L, et al. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunol Immunother. 2000;48(12):661–72.PubMedCrossRef
49.
50.
Markov OO, Mironova NL, Maslov MA, et al. Novel cationic liposomes provide highly efficient delivery of DNA and RNA into dendritic cell progenitors and their immature offsets. J Control Release. 2012;160(2):200–10.PubMedCrossRef
51.••
Morse MA, Niedzwiecki D, Marshall JL, et al. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg. 2013;258(6):879–86. The authors show that dendritic cell and poxvector vaccines have similar activity in increase in survival in patients with resected metastases of colorectal cancer and survival benefit for vaccinated patients than for a contemporary unvaccinated group.PubMedCrossRef
52.
Sakakibara M, Kanto T, Hayakawa M, et al. Comprehensive immunological analyses of colorectal cancer patients in the phase I/II study of quickly matured dendritic cell vaccine pulsed with carcinoembryonic antigen peptide. Cancer Immunol Immunother. 2011;60(11):1565–75.PubMedCrossRef
53.
Lesterhuis WJ, De Vries IJ, Schreibelt G, et al. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Anticancer Res. 2010;30(12):5091–7.PubMed
54.
Lesterhuis WJ, de Vries IJ, Aarntzen EA, et al. A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients. Br J Cancer. 2010;103(9):1415–21.PubMedPubMedCentralCrossRef
55.
Burgdorf SK. Dendritic cell vaccination of patients with metastatic colorectal cancer. Dan Med Bull. 2010;57(9):B4171.PubMed
56.
Barth Jr RJ, Fisher DA, Wallace PK, et al. A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival. Clin Cancer Res. 2010;16(22):5548–56.PubMedPubMedCentralCrossRef
57.
Kavanagh B, Ko A, Venook A, et al. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother. 2007;30(7):762–72.PubMedCrossRef
58.
Babatz J, Röllig C, Löbel B, et al. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol Immunother. 2006;55(3):268–76.PubMedCrossRef
59.
Morse MA, Clay TM, Hobeika AC, et al. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res. 2005;11(8):3017–24.PubMedCrossRef
60.
Liu KJ, Wang CC, Chen LT, et al. Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin Cancer Res. 2004;10(8):2645–51.PubMedCrossRef
61.
Morse MA, Nair SK, Mosca PJ, et al. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Investig. 2003;21(3):341–9.CrossRef
62.
Sadanaga N, Nagashima H, Mashino K, et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res. 2001;7(8):2277–84.PubMed
63.
Fong L, Hou Y, Rivas A, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A. 2001;98(15):8809–14.PubMedPubMedCentralCrossRef
64.
Tesniere A, Schlemmer F, Boige V, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29(4):482–91.PubMedCrossRef
65.•
Naidoo J, Page DB, Wolchok JD. Immune checkpoint blockage. Hematol Oncol Clin N Am. 2014;28(3):585–600. The authors summarize the mechanism of action, preclinical development, and subsequent clinical studies of immune checkpoint antibodies in melanoma.CrossRef
Metadata
Title
Dendritic Cell Cancer Vaccines for Treatment of Colon Cancer
Authors
Osama E. Rahma
Zaw W. Myint
Bassam Estfan
Publication date
01-12-2014
Publisher
Springer US
Published in
Current Colorectal Cancer Reports / Issue 4/2014
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-014-0243-4

Other articles of this Issue 4/2014

Current Colorectal Cancer Reports 4/2014 Go to the issue

Molecular Biology (S Anant, Section Editor)

DNA Methylation and Colorectal Cancer

Translational Colorectal Oncology (Y Jiang, Section Editor)

Anti-EGFR Resistance in Colorectal Cancer: Current Knowledge and Future Perspectives

Translational Colorectal Oncology (Y Jiang, Section Editor)

Can Circulating MicroRNAs Become the Test of Choice for Colorectal Cancer?

Molecular Biology (S Anant, Section Editor)

Mechanisms by Which Pleiotropic Amphiphilic n−3 PUFA Reduce Colon Cancer Risk

Molecular Biology (S Anant, Section Editor)

Targeting Cancer Stem Cells by Phytochemicals: a Multimodal Approach to Colorectal Cancer

Translational Colorectal Oncology (Y Jiang, Section Editor)

Are NSAIDs Coming Back to Colorectal Cancer Therapy or Not?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits